Diagnostics

RMDM Diagnostics is the next stage in delivering the pioneering blood test and imaging screening program for early cancer detection.

Working with Dr Johannes Coy, the virtuoso behind the development of EDIM, we are building upon robust foundations to deliver an affordable and non-invasive blood test and screening program that is transforming the way we view and diagnose cancer.

PanTum Detect: A blood test for the early detection of tumour types

PanTum Detect is a pioneering diagnostic test that can filter asymptomatic healthy individuals by screening for the presence of silently growing benign, premalignant or malignant tumours.

Safe, proven and reliable, PanTum Detect is made possible by the innovative EDIM (Epitope Detection in Macrophages) technology Dr Coy and his team developed.

EDIM draws upon the natural mechanism of the immune system to detect universal biomarkers Apo10 and TKTL1 – one of which is detectable in all phases of tumour genesis (Apo10) . These two genes have been pivotal in developing EDIM technology. Apo10 presents with the earliest signs of tumour development, whilst TKTL1 manifests at the early signs of tumour malignancy and metastasis. The TKTL1 biomarker was discovered and patented by Dr Coy.

Two blood vials and protective eyewear on a sterile, medical surface

Read The FAQs

A young, dark haired female in a medical robe, sitting on a hospital bed and discussing notes with a female doctor

Early Cancer Diagnosis

With over 200 different types of cancer, recent research data published by Cancer Research UK shows that 1 in 2 people in the UK will get cancer in their lifetime.

PanTum Detect can provide early cancer diagnosis, giving people enough time to make positive and impactful lifestyle changes.

Detecting tumours before they evolve and spread into life-threatening cancers gives time for targeted medical intervention at an early stage, increasing survival rates and preventing relapses.

Explore some of the most commonly asked questions.

Screening Program: PanTum Detect + PET/CT

High Specificity | High Sensitivity | Non-invasive | Quick and Simple Process | Affordable

PanTum Detect provides a very high test accuracy (sensitivity of 95.21% and a specificity of 99.53%), meaning that missed tumours and false positives are highly unlikely.

In addition, it is a quick and simple, non-invasive process that is affordable, allowing for regular, annual testing.

The screening program combines PanTum Detect with an MRI, PET/CT scan and physician consultation, which allows for safe cancer screening by filtering out non-cancer suspicious patients.

Most potentially dangerous tumours are able to be detected at a very early stage using imaging methods (such as MRI, PET/CT, etc.).

However, due to the high costs and radiation exposure (e.g. PET/CT), these procedures are not suitable for use without tumour-suspicion.

This convenient blood test combined with imaging empowers us all to detect cancer early, increasing the success rate of cancer treatment.

With this technology, we can replace fear with a simple step to healthier lives.